Díez-Martín José L, Balsalobre Pascual, Re Alessandro, Michieli Mariagrazia, Ribera José M, Canals Carmen, Conde Eulogio, Rosselet Anne, Gabriel Ian, Varela Rosario, Allione Bernardino, Cwynarski Kate, Genet Philippe, Espigado Ildefonso, Biron Pierre, Schmitz Norbert, Hunter Anne E, Ferrant Augustin, Guillerm Gaelle, Hentrich Mark, Jurado Manuel, Fernández Pascual, Serrano David, Rossi Giuseppe, Sureda Anna
Hematology Department, Hospital General Universitario Gregorio Marañon, Madrid, Spain.
Blood. 2009 Jun 4;113(23):6011-4. doi: 10.1182/blood-2008-12-195388. Epub 2009 Mar 23.
Autologous stem cell transplantation (ASCT) has been successfully used in HIV-related lymphoma (HIV-Ly) patients on highly active antiretroviral therapy. We report the first comparative analysis between HIV-Ly and a matched cohort of HIV(-) lymphoma patients. This retrospective European Group for Blood and Marrow Transplantation study included 53 patients (66% non-Hodgkin and 34% Hodgkin lymphoma) within each cohort. Both groups were comparable except for the higher proportion of males, mixed-cellularity Hodgkin lymphoma and patients receiving granulocyte colony-stimulating factor before engraftment and a smaller proportion receiving total body irradiation-based conditioning within the HIV-Ly cohort. Incidence of relapse, overall survival, and progression-free survival were similar in both cohorts. A higher nonrelapse mortality within the first year after ASCT was observed in the HIV-Ly group (8% vs 2%), predominantly because of early bacterial infections, although this was not statistically significant and did not influence survival. Thus, within the highly active antiretroviral therapy era, HIV patients should be considered for ASCT according to the same criteria adopted for HIV(-) lymphoma patients.
自体干细胞移植（ASCT）已成功应用于接受高效抗逆转录病毒治疗的HIV相关淋巴瘤（HIV-Ly）患者。我们报告了HIV-Ly患者与匹配的HIV（-）淋巴瘤患者队列之间的首次比较分析。这项欧洲血液和骨髓移植组的回顾性研究在每个队列中纳入了53例患者（66%为非霍奇金淋巴瘤，34%为霍奇金淋巴瘤）。除了HIV-Ly队列中男性比例更高、混合细胞性霍奇金淋巴瘤患者以及移植前接受粒细胞集落刺激因子治疗的患者比例更高，而接受基于全身照射的预处理的患者比例更低外，两组具有可比性。两个队列中的复发率、总生存率和无进展生存率相似。在HIV-Ly组中，观察到ASCT后第一年的非复发死亡率更高（8%对2%），主要是由于早期细菌感染，尽管这在统计学上不显著且不影响生存。因此，在高效抗逆转录病毒治疗时代，应根据适用于HIV（-）淋巴瘤患者的相同标准考虑对HIV患者进行ASCT。
